Loading
A radioactive version of the hormone mimic used for the scan; it homes to neuroendocrine tumour cells and irradiates them from inside.
177Lu-DOTATATE (Lutathera; NETTER-1 second line, NETTER-2 first line in grade 2-3) is the reference. 177Lu-edotreotide (ITM-11, COMPETE: PFS 23.9 vs 14.1 months vs everolimus; FDA PDUFA 28 August 2026) is the second beta-emitter. Alpha PRRT with 212Pb-DOTAMTATE (AlphaMedix, Breakthrough designation; phase 2 ORR 54% in PRRT-naive) and 225Ac-DOTATATE (RYZ101, ACTION-1 phase 3) aims at beta-refractory disease. Antagonist ligands (177Lu-satoreotide) bind more receptor sites than agonists.
An SSTR2-binding peptide is chelated to a therapeutic radionuclide and internalised by the tumour cell; beta (177Lu) or alpha (212Pb, 225Ac) emission; usually four cycles.
Nothing in the corpus depends on this yet.
Dependencies are what this technology cannot be delivered without: manufacturing steps, instruments, software, upstream methods. See its full chain on the map.
A second lutetium radioligand for neuroendocrine tumours that beat the standard pill everolimus in a head-to-head trial and is awaiting an FDA decision.
An alpha-particle version of neuroendocrine radioligand therapy that produced responses in over half of patients who had never had PRRT, with FDA Breakthrough designation.
The PET scan for neuroendocrine tumours that finds far more disease than older scans and confirms eligibility for lutetium radioligand therapy (the theranostic pair).
Query for this technology: (TITLE:"Peptide receptor radionuclide therapy" OR ABSTRACT:"Peptide receptor radionuclide therapy" OR TITLE:"PRRT" OR ABSTRACT:"PRRT") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Peptide receptor radionuclide therapy (PRRT), not a curated reading list.
Shares Actinium-225 DOTATATE, PRRT (peptide receptor radionuclide therapy), Gallium-68 DOTATATE (and Cu-64 DOTATATE), Lung neuroendocrine tumours (typical and atypical carcinoid).
Shares Dosimetry-personalised PRRT instead of four fixed cycles, Grade 3 well-differentiated neuroendocrine tumour, Lung neuroendocrine tumours (typical and atypical carcinoid), Lutetium-177 dotatate.
Shares NETTER-1, PRRT (peptide receptor radionuclide therapy), Grade 3 well-differentiated neuroendocrine tumour, Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4).
Shares Glucagonoma, VIPoma, Somatostatinoma, Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4).
Shares RayzeBio (BMS), ITM Isotope Technologies Munich, Orano Med, Actinium-225 DOTATATE.
Shares RayzeBio (BMS), 212Pb-DOTAMTATE, ITM Isotope Technologies Munich, Orano Med.
Shares Glucagonoma, VIPoma, Somatostatinoma, COMPETE.
Shares Actinium-225 DOTATATE, Lutetium-177 dotatate, Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours.